Copyright
©2013 Baishideng.
World J Pharmacol. Sep 9, 2013; 2(3): 65-72
Published online Sep 9, 2013. doi: 10.5497/wjp.v2.i3.65
Published online Sep 9, 2013. doi: 10.5497/wjp.v2.i3.65
Group | Subgroup | Quick reference | Features |
A | A | Small tumor | size ≤ 3 mm |
B | B | Larger tumor | Size > 3 mm |
Macula | ≤ 3 mm to foveola | ||
Juxtapapillary | ≤ 1.5 mm to disc | ||
Subretinal fluid | Clear subretinal fluid ≤ 3 mm from margin | ||
C | C1 | Focal seeds | Subretinal seeds ≤ 3 mm from tumor |
C2 | Vitreous seeds ≤ 3 mm from tumor | ||
C3 | Both subretinal and vitreous seeds ≤ 3 mm from tumor | ||
D | D1 | Diffuse seeds | Subretinal seeds > 3 mm from tumor |
D2 | Vitreous seeds > 3 mm from tumor | ||
D3 | Both subretinal and vitreous seeds > 3 mm from tumor | ||
E | E | Extensive retinoblastoma | > 50% globe involvement or |
Neovascular glaucoma | |||
hemorrhage in anterior chamber, vitreous, or subretinal space | |||
Invasion to postlaminar optic nerve, choroid (> 2 mm), sclera, orbit, anterior chamber |
- Citation: Shah NV, Houston SK, Murray TG. Retinoblastoma and treatment: A current evaluation of advanced therapy. World J Pharmacol 2013; 2(3): 65-72
- URL: https://www.wjgnet.com/2220-3192/full/v2/i3/65.htm
- DOI: https://dx.doi.org/10.5497/wjp.v2.i3.65